This site is intended for healthcare professionals outside the US.


Positive treatment effect across all pre-specified subgroups1

“AFINITOR (everolimus) plus exemestane showed a positive treatment effect across all pre-specified subgroups compared to exemestane plus placebo”
*AFINITOR is indicated for the treatment of hormone receptor–positive, HER2/neu negative advanced breast cancer, in
combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a nonsteroidal aromatase inhibitor.
Other than NSAI.
ABC, advanced breast cancer; AFI, AFINITOR; ECOG, Eastern Cooperative Oncology Group; EXE, exemestane; HR+, hormone receptor-positive; NSAI, nonsteroidal aromatase inhibitor; PFS, progression-free survival; PgR, progesterone receptor; PBO, placebo.
Adapted with kind permission from Springer Science+Business Media: Adv Ther. Everolimus Plus Exemestane in Postmenopausal Patients With HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. 2013;30(10):870-884. Yardley DA, Noguchi S, Pritchard KI, et al. Figure 2.
  1. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870-884.
  2. AFINITOR [summary of product characteristics]. Novartis Pharma AG; 2016.